ERRATUM

Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

Philip Q. Bao, MD¹, Ramesh K. Ramanathan, MD², Alyssa Krasinkas, MD³, Nathan Bahary, MD⁴, Barry C. Lembersky, MD⁴, David L. Bartlett, MD⁵, Steven J. Hughes, MD⁵, Kenneth K. Lee, MD⁵, A. James Moser, MD⁵, and Herbert J. Zeh III, MD⁵

¹Department of Surgery, Stony Brook University Hospital, Stony Brook, NY; ²Virginia G. Piper Cancer Center, Scottsdale, AZ; ³Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴Department of Medical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁵Department of Surgery, Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA

**ERRATUM TO: ANN SURG ONCOL
(2011) 18:1122–1129
DOI 10.1245/S10434-010-1401-9**

The article entitled, “Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected

Pancreatic Cancer” by Bao et al (Ann Surg Oncol [2011] 18:1122–1129 DOI [10.1245/s10434-010-1401-9](https://doi.org/10.1245/s10434-010-1401-9)) did not correctly identify the two corresponding authors.

The two corresponding authors for this paper are: A. James Moser, MD (moseraj@upmc.edu) and Herbert J. Zeh III, MD (zehxhx@upmc.edu).

The online version of the original article can be found under doi:[10.1245/s10434-010-1401-9](https://doi.org/10.1245/s10434-010-1401-9).

© Society of Surgical Oncology 2011

Published Online: 22 April 2011

A. James Moser, MD
e-mail: moseraj@upmc.edu

H. J. Zeh III, MD
e-mail: zehxhx@upmc.edu